Hypercoagulability: Clinical assessment and treatment

Southern Medical Journal

Volumn 94, Issue 10, 2001, Pages 1013-1020

  Abramson, Neil ^a   Abramson, Simeon ^a,b  

^a Baptist Regional Cancer Institute   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

The best clue for the presence of hypercoagulability is a positive family history; The defects that are responsible for hypercoagulability can be divided into inherited defects and acquired forms

Indexed keywords

PROTEIN C;

ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PREGNANCY; REVIEW; RISK FACTOR; THROMBOPHILIA;

ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PREGNANCY; PROTEIN C; RISK FACTORS; THROMBOPHILIA;

EID: 0035489312     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-200110000-00014     Document Type: Article

References (28)

1. Bauer KA: Hypercopgulable states. Hematology: Basic Principles and Practice. Hoffman R, Benz EJ Jr, Shattil SJ, et al (eds). New York, Churchill Livingstone, 1995, pp 1781-1795
2. Allaart CF, Briet E: Familial venous thrombophilia. Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, et al (eds). London, Churchill Livingstone, 1994, p 1349
3. Svensson PJ, Dahlback B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517-522
4. Koster T, Rosendaal FR, de Ronde H, et al: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:1503-1506
5. Griffin JH, Evatt B, Wideman C, et al: Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82:1989-1993
6. Harris JM, Abramson N: Evaluation of recurrent thrombosis and hypercoagulability. Am Fam Physician 1997; 56:1591-1596,1601
7. Gandrille S, Greengard JS, Alhenc-Gelas M, et al: Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM. Blood 1995; 86:219-224
8. Bertina RM, Koeleman BP, Koster T, et al: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64
9. Griffin JH, Heeb MJ, Kojima Y, et al: Activated protein C resistance: molecular mechanisms. Thromb Haemost 1995; 74:444-448
10. Zivelin A, Griffin JH, Xu X, et al: A single genetic origin for a common caucasian risk factor for venous thrombosis. Blood 1997; 89:397-402
11. Rees DC, Cox M, Clegg JB: World distribution of factor V Leiden. Lancet 1995; 346:1133-1134
12. Cox MJ, Rees DC, Martinson JJ, et al: Evidence for a single origin of factor V Leiden. Br J Haematol 1996; 92:1022-1025
13. Middeldorp S, Henkens CM, Koopman MM, et al: The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128:15-20
14. Hellgren M, Svensson PJ, Dahlback B: Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173:210-213
15. Brenner B, Lanir N, Thaler I: HELLP syndrome associated with factor V R506Q mutation. Br J Haematol 1996; 92:999-1001
16. Cumming AM, Tait RC, Fildes S, et al: Diagnosis of APC Resistance during pregnancy. Br J Haematol 1996; 92:1026-1029
17. Cumming AM, Tait RC, Fildes S, et al: Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90:725-727
18. Mathonnet F, de Mazancourt P, Bastenaire B, et al: Activated protein C sensitivity ratio in pregnant women at delivery Br J Haematol 1996; 92:244-246
19. Olivieri O, Friso S, Manzato F, et al: Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91:465-470
20. Heinrich J, Budde T, Assmann G: Mutation in the factor V gene and the risk of myocardial infarction (Letter). N Engl J Med 1995; 333:881
21. Ridker PM, Hennekens CH, Lindpaintner K, et al: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. A Engl J Med 1995; 332:912-917
22. Koeleman BP, Reitsma PH, Allaart CF, et al: Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84:1031-1035
23. Poort SR, Rosendaal FR, Reitsma PH, et al: A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703
24. Ames PR, Tommasino C, D'Andrea G, et al: Thrombophilic genotypes in subjects with idiopathic antiphospholipid antibodies - prevalence and significance. Thromb Haemost 1998; 79:46-49
25. Kamphuisen PW, Lensen R, Houwing-Duistermaat JJ, et al: Heritability of elevated factor VIII antigen levels in factor V Leiden families with thrombophilia. Br J Haematol 2000; 109:519-522
26. Olds RJ, Fitches AC, Geary CP: The multigenic basis for venous thrombosis. Br J Haematol 2000; 109:508-511
27. Mandel H, Brenner B, Berant M, et al: Coexistence of hereditary homocystinuria and factor V Leiden - effect on thrombosis. N Engl J Med 1996; 334:763-768
28. den Heijer M, Koster T, Blom HJ, et al: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334:759-762